717 results on '"Peters, Anju T."'
Search Results
2. IL-13 and IL-13–induced periostin levels are specifically decreased in patients following endoscopic sinus surgery for chronic rhinosinusitis
3. Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2)
4. Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation Study
5. Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma
6. Associations Between Chronic Rhinosinusitis and the Development of Non–Cystic Fibrosis Bronchiectasis
7. Consultation for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Clinical Presentation, Diagnostic Workup, and Treatment Options
8. The Management of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With Biologics
9. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis
10. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps
11. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
12. The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps
13. Prevalence of Bronchiectasis in Patients with Chronic Rhinosinusitis in a Tertiary Care Center
14. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps
15. ASSESSING THE IMPACT OF ASTHMA CONTROL QUESTIONNAIRE SCORE CUTOFFS WITHIN THE MULTICOMPONENT CLINICAL REMISSION ENDPOINT ON CLINICAL OUTCOMES: TRAVERSE OPEN-LABEL STUDY
16. BASELINE CHARACTERISTICS AND COEXISTING TYPE 2 INFLAMMATORY DISEASES OF PATIENTS WITH ASTHMA INITIATING DUPILUMAB IN A REAL-WORLD SETTING: THE RAPID REGISTRY
17. BASELINE CHARACTERISTICS OF PATIENTS ON MEDIUM- VS HIGH-DOSE INHALED CORTICOSTEROIDS IN PATIENTS INITIATING DUPILUMAB IN A REAL-WORLD CLINICAL SETTING: THE RAPID REGISTRY
18. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19
19. Development and Preliminary Validation of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO)
20. Responsiveness and Convergent Validity of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO)
21. Clinical factors associated with acute exacerbations of chronic rhinosinusitis
22. Current and Future Treatments of Rhinitis and Sinusitis
23. Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis
24. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis
25. 1237. Inpatients with a beta-lactam antibiotic allergy label (BAAL) and unrevealed tolerance: A prevalence study aimed to prioritize non-invasive delabeling for antimicrobial stewardship programs
26. Impact of dupilumab across seasons in patients with type 2 uncontrolled, moderate-to-severe asthma
27. Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps
28. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis
29. Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps
30. DUPILUMAB SAFETY AND EFFICACY IN A REAL-WORLD CLINICAL SETTING: THE RAPID ASTHMA REGISTRY
31. Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting
32. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52.
33. BASELINE CHARACTERISTICS OF PATIENTS WITH MODERATE-TO-SEVERE ASTHMA WITH AND WITHOUT COEXISTING ATOPIC DERMATITIS PARTICIPATING IN THE RAPID REGISTRY STUDY
34. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52
35. Evaluation and treatment of rhinosinusitis with primary antibody deficiency in adults: Evidence‐based review with recommendations
36. Sinus inflammation and chronic rhinosinusitis are associated with a diagnosis of new onset asthma in the following year
37. The Clinical Significance of Specific Antibody Deficiency (SAD) Severity in Chronic Rhinosinusitis (CRS)
38. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease
39. Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H,K-ATPase
40. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up.
41. Risk of new onset and prevalent disease in chronic rhinosinusitis: a prospective cohort study
42. Rhinitis and rhinosinusitis
43. Infectious Chronic Rhinosinusitis
44. African American Patients with Chronic Rhinosinusitis Have a Distinct Phenotype of Polyposis Associated with Increased Asthma Hospitalization
45. Complications of Rhinitis
46. Increased expression of the epithelial anion transporter pendrin/SLC26A4 in nasal polyps of patients with chronic rhinosinusitis
47. Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polyps
48. Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease
49. Clinical Characteristics of Adults With Chronic Rhinosinusitis and Specific Antibody Deficiency
50. Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.